|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammation in irritable bowel syndrome:Myth or newtreatment target?显示文摘Low-grade intestinal inflammation plays a key role in the pathophysiology of irritable bowel syndrome(IBS), and this role is likely to be multifactorial. The aim of this review was to summarize the evidence on the spectrum of mucosal inflammation in IBS, highlighting the relationship of this inflammation to the pathophysiology of IBS and its connection to clinical practice. We carried out a bibliographic search in Medline and the Cochrane Library for the period of January 1966 to December 2014, focusing on publications describing an interaction between inflammation and IBS. Several evidences demonstrate microscopic and molecular abnormalities in IBS patients. Understanding the mechanisms underlying low-grade inflammation in IBS may help to design clinical trials to test the efficacy and safety of drugs that target this pathophysiologic mechanism. | Emanuele Sinagra Giancarlo Pompei Giovanni Tomasello Francesco Cappello Gaetano Cristian Morreale Georgios Amvrosiadis Francesca Rossi Attilio Ignazio Lo Monte Aroldo Gabriele Rizzo Dario Raimondo | 2016 | World Journal of Gastroenterology2016，22，7： | 16 |
| 2 | New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond显示文摘Irritable bowel syndrome(IBS)is a chronic,recurring,and remitting functional disorder of the gastrointestinal tract characterized by abdominal pain,distention,and changes in bowel habits.Although there are several drugs for IBS,effective and approved treatments for one or more of the symptoms for various IBS subtypes are needed.Improved understanding of pathophysiological mechanisms such as the role of impaired bile acid metabolism,neurohormonal regulation,immune dysfunction,the epithelial barrier and the secretory properties of the gut has led to advancements in the treatment of IBS.With regards to therapies for restoring intestinal permeability,multiple studies with prebiotics and probiotics are ongoing,even if to date their efficacy has been limited.In parallel,much progress has been made in targeting low-grade inflammation,especially through the introduction of drugs such as mesalazine and rifaximin,even if a better knowledge of the mechanisms underlying the low-grade inflammation in IBS may allow the design of clinical trials that test the efficacy and safety of such drugs.This literature review aims to summarize the findings related to new and investigational therapeutic agents for IBS,most recently developed in preclinical as well as Phase 1 and Phase 2clinical studies. | Emanuele Sinagra Gaetano Cristian Morreale Ghazaleh Mohammadian Giorgio Fusco Valentina Guarnotta Giovanni Tomasello Francesco Cappello Francesca Rossi Georgios Amvrosiadis Dario Raimondo | 2017 | World Journal of Gastroenterology2017，23，36： | 14 |
| 3 | Current approach in the treatment of hepatocellular ca显示文摘Hepatocellular carcinoma (HCC) is the most common malignant hepatobiliary disease; it is responsible for about 1 million deaths per year. Risk factors include hepatitis B and C, hepatic cirrhosis, including alcohol related hepatitis, metabolic and nutritional hepatic damage. The main modality of diffusion is intrahepatic in the natural course of the disease. There are two leading types of treatment: local and systemic. Surgical resection and liver transplantation constitute the most appropriate local treatments and are considered the only real possibility for recovery. Other local approaches include: radiofrequency ablation, percutaneous ethanol ablation, hepatic endoarterial chemoembolization and intrahepatic radiotherapy (SIRT: selective internal radiation therapy). These last treatments are used to control the disease when surgery or transplantation is not achievable; in some cases they are able to prolong survival while theyconstitute mainly a palliative treatment. Systemic treatments include: chemotherapy, immunological and hormonal therapies and, more recently, the introduction of new specific molecular target drugs. At the moment, in this group, the only drug that has given positive results during phase trials (SHARP study) is Sorafenib.Sorafenib represents the only primary systemic therapy that has demonstrated, unlike the other treatments previously described, an increase in survival rate in patients affected with advanced HCC. Currently, other studies are taking place that are further developing the potential of this drug. These studies, including phase trials, aredirected in order to test the activity and safety of new emerging drugs with targeted activity. Examples of these new agents are: Sunitinib, Gef itinib, Cetuximab, Bevacizumab and Erlotinib. | Luigi Rossi Federica Zoratto Anselmo Papa Francesca Iodice Marina Minozzi Luigi Frati Silverio Tomao | 2010 | World Journal of Gastrointestinal Oncology2010，2，9： | 11 |
| 4 | Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis显示文摘AIM:To investigated the molecular cause of very early-onset ulcerative colitis(UC)in an 18-mo-old affected child.METHODS:We analysed the interleukin-10(IL10)receptor genes at the DNA and RNA level in the proband and his relatives.Beta catenin and tumor necrosis factor-α(TNFα)receptors were analysed in the proteins extracted from peripheral blood cells of the proband,his relatives and familial adenomatous polyposis(FAP)and PTEN hamartoma tumor syndrome(PHTS)patients.Samples were also collected from the proband’s inflamed colorectal mucosa and compared to healthy and tumour mucosa collected from a FAP patient and patients affected by sporadic colorectal cancer(CRC).Finally,we examined mesalazine and azathioprine effects on primary fibroblasts stabilised from UC and FAP patients.RESULTS:Our patient was a compound heterozygote for the IL10RB E47K polymorphism,inherited from his father,and for a novel point mutation within the IL10RA promoter(the-413G->T),inherited from his mother.Beta catenin and tumour necrosis factorαreceptors-Ⅰ(TNFRI)protein were both over-expressed in peripheral blood cells of the proband’s relatives more than the proband.However,TNFRII was over-expressed only in the proband.Finally,both TNFα-receptors were shown to be under-expressed in the inflamed colon mucosa and colorectal cancer tissue compared to healthy colon mucosa.Consistent with this observation,mesalazine and azathioprine induced,in primary fibroblasts,IL10RB and TNFRII over-expression and TNFRI and TNFαunder-expression.We suggest thatβ-catenin and TNFRI protein expression in peripheral blood cells could represent molecular markers of sub-clinical disease in apparently healthy relatives of patients with early-onset UC.CONCLUSION:A synergistic effect of several variant alleles of the IL10 receptor genes,inherited in a Mende-lian manner,is involved in UC onset in this young child. | Martina Galatola Erasmo Miele Caterina Strisciuglio Lorella Paparo Daniela Rega Paolo Delrio Francesca Duraturo Massimo Martinelli Giovanni Battista Rossi Annamaria Staiano Paola Izzo Marina De Rosa | 2013 | World Journal of Gastroenterology2013，19，46： | 7 |
| 5 | 人类精液高粘度:患病率、发病机理和治疗方面显示文摘本文旨在(a)测量低生育力夫妇人群中男性精液高粘度(SHV)的发生率;(b)探讨SHV和生殖道感染或炎症的相关性;(c)评价SHV各种治疗方式的疗效:(d)测定治疗SHV成功后的精子动力参数。我们对1833对不孕夫妇中的男性进行了回顾性研究。对其中的52个名患有SHV的男性进行临床、精液细菌学和超声检查,并对SHV进行分级,分为轻度(2cm〈精液拉线长度≤4cm),中度(4cm〈精液拉线长度≤6cm),和重度(精液拉线长度〉6cm)。研究发现SHV的发生率为26.2%(480/1833),其中13.2%为轻度,6.6%为中度,6.4%为重度。治疗发现成功率仅为52.0%(27/52),主要是精液培养阳性且SHV为轻度的男性。在这些患者中,前进运动活力的百分比,直线速度和线性度比治疗前均有显著提高。SHV一般发生在低生育力的男性。48.0%的SHV发病机制与感染/炎症因素有关,因此,生化、酶或遗传因素对此有一定的影响。 | Jlenia Elia Michele Delfino Norina Imbrogno Francesca Capogreco Marco Lucarelli Tiziana Rossi Fernando Mazzilli | 2009 | Asian Journal of Andrology2009，11，5： | 5 |
| 6 | Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs显示文摘Hepatitis B virus(HBV) reactivation in rheumatoid arthritis(RA) patients undergoing biological therapy is not infrequent. This condition can occur in patients with chronic hepatitis B as well as in patients with resolved HBV infection. Current recommendations are mainlyfocused on prevention and management strategies of viral reactivation under tumor necrosis factor-α inhibitors or chimeric monoclonal antibody rituximab. In recent years, growing data concerning HBV reactivation in RA patients treated with newer biological drugs like tocilizumab and abatacept have cumulated. In this review, epidemiology, pathogenesis and natural history of HBV infection have been revised first, mainly focusing on the role that specific therapeutic targets of current biotechnological drugs play in HBV pathobiology; finally we have summarized current evidences from scientific literature, including either observational studies and case reports as well, concerning HBV reactivation under different classes of biological drugs in RA patients. Taking all these evidences into account, some practical guidelines for screening, vaccination, prophylaxis and treatment of HBV reactivation have been proposed. | Francesca De Nard Monica Todoerti Vittorio Grosso Sara Monti Silvia Breda Silvia Rossi Carlomaurizio Montecucco Roberto Caporali | 2015 | World Journal of Hepatology2015，7，3： | 3 |
| 7 | Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy显示文摘 | Aurelio Sgalambro Iacopo Olivotto Alessandra Rossi Stefano Nistri Katia Baldini Massimo Baldi Pierluigi Stefano David Antoniucci Francesca Garbini Franco Cecchi Magdi H. Yacoub | 2010 | The Journal of Thoracic and Cardiovascular Surgery2010，，5： | 2 |
| 8 | Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma显示文摘 | Sandro Rossi Giorgia Ghittoni Valentina Ravetta Francesca Torello Viera Laura Rosa Martina Serassi Mara Scabini Alessandro Vercelli Carmine Tinelli Barbara Dal Bello Peter N. Burns Fabrizio Calliada | 2008 | European Radiology2008，，8： | 2 |
| 9 | Hazard and population vulnerability analysis: a step towards landslide risk assessment显示文摘In this paper, an attempt to analyse landslide hazard and vulnerability in the municipality of Pahuatlán, Puebla, Mexico, is presented. In order to estimate landslide hazard, the susceptibility,magnitude(area-velocity ratio) and landslide frequency of the area of interest were produced based on information derived from a geomorphological landslide inventory; the latter was generated by using very high resolution satellite stereo pairs along with information derived from other sources(Google Earth,aerial photographs and historical information).Estimations of landslide susceptibility were determined by combining four statistical techniques:(i) logistic regression,(ii) quadratic discriminant analysis,(iii) linear discriminant analysis, and(iv)neuronal networks. A Digital Elevation Model(DEM)of 10 m spatial resolution was used to extract the slope angle, aspect, curvature, elevation and relief.These factors, in addition to land cover, lithology anddistance to faults, were used as explanatory variables for the susceptibility models. Additionally, a Poisson model was used to estimate landslide temporal frequency, at the same time as landslide magnitude was obtained by using the relationship between landslide area and the velocity of movements. Then,due to the complexity of evaluating it, vulnerability of population was analysed by applying the Spatial Approach to Vulnerability Assessment(SAVE) model which considered levels of exposure, sensitivity and lack of resilience. Results were expressed on maps on which different spatial patterns of levels of landslide hazard and vulnerability were found for the inhabited areas. It is noteworthy that the lack of optimal methodologies to estimate and quantify vulnerability is more notorious than that of hazard assessments.Consequently, levels of uncertainty linked to landslide risk assessment remain a challenge to be addressed. | Franny G.MURILLO-GARCíA Mauro ROSSI Francesca ARDIZZONE Federica FIORUCCI Irasema ALCáNTARA-AYALA | 2017 | Journal of Mountain Science2017，14，7： | 2 |
| 10 | Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma显示文摘 | Sandro Rossi Giorgia Ghittoni Valentina Ravetta Francesca Torello Viera Laura Rosa Martina Serassi Mara Scabini Alessandro Vercelli Carmine Tinelli Barbara Dal Bello Peter N. Burns Fabrizio Calliada | 2008 | European Radiology2008，，8： | 1 |
| 11 | Refinements in maximum likelihood inference on spatial autocorrelation in panel data显示文摘 | Peter M. Robinson Francesca Rossi | 2015 | Journal of Econometrics2015，，： | 1 |
| 12 | Free peritoneal tumor cells detection in gastric and colorectal cancer patients显示文摘 | Simone Rossi Del Monte Danilo Ranieri Francesca Mazzetta Andrea Kazemi Nava Salvatore Raffa Maria Rosaria Torrisi Vincenzo Ziparo | 2012 | J Surg Oncol2012，，1： | 1 |
| 13 | Spray dried amikacin powder for inhalation in cystic fibrosis patients: A quality by design approach for product construction显示文摘 | Silvia Belotti Alessandra Rossi Paolo Colombo Ruggero Bettini Dimitrios Rekkas Stavros Politis Gaia Colombo Anna Giulia Balducci Francesca Buttini | 2014 | International Journal of Pharmaceutics2014，，： | 1 |
| 14 | Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma显示文摘 | Sandro Rossi Giorgia Ghittoni Valentina Ravetta Francesca Torello Viera Laura Rosa Martina Serassi Mara Scabini Alessandro Vercelli Carmine Tinelli Barbara Dal Bello Peter N. Burns Fabrizio Calliada | 2008 | European Radiology2008，，8： | 1 |
| 15 | Portal hypertensive gastropathy in cirrhotics without varices: a case–control study显示文摘 | Enrico Maria Zardi Giorgia Ghittoni Domenico Margiotta Francesca Torello Viera Francesco Di Matteo Sandro Rossi | 2015 | European Journal of Gastroenterology & Hepatology2015，，1： | 1 |
| 16 | Photothermal effects in connective tissues mediated by laser-activated gold nanorods显示文摘 | Fulvio Ratto Paolo Matteini Francesca Rossi | 2009 | Biology and Medicine2009，5，2： | 1 |
| 17 | Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model显示文摘 | Paolo Sbano Aldo Cuccia Benedetta Mazzanti Serena Urbani Betti Giusti Ilaria Lapini Luciana Rossi Rosanna Abbate Giuseppina Marseglia Genni Nannetti Francesca Torricelli Clelia Miracco Alberto Bosi Michele Fimiani Riccardo Saccardi | 2008 | Archives of Dermatological Research2008，，3： | 1 |
| 18 | Semiring-based constraint solving and optimization显示文摘 | Stefano Bistarelli Ugo Montanari Francesca Rossi | 1997 | Journal of the ACM1997，44，2： | 1 |
| 19 | Landslide volumes and landslide mobilization rates in Umbria, central Italy显示文摘 | Fausto Guzzetti Francesca Ardizzone Mauro Cardinali Mauro Rossi Daniela Valigi | 2008 | Earth and Planetary Science Letters2008，，3： | 1 |
| 20 | Alternative splicing and nonsense-mediated mRNA decay in the regulation of a new adenomatous polyposis coli transcript显示文摘 | Marina De Rosa Gemma Morelli Elena Cesaro Francesca Duraturo Mimmo Turano Giovanni B. Rossi Paolo Delrio Paola Izzo | 2007 | Gene2007，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员